Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO101 in Age-Related Sarcopenia
NCT03452488Phase 2Completed
- Sponsor
- Biophytis
- Start
- Feb 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of 20-hydroxyecdysone in Sarcopenia (3 arms), sponsored by Biophytis. Primary endpoint: Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test. Started Feb 2017; status: completed.
02
Drugs
20-hydroxyecdysone
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT03452488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452488.